Marburg Vaccine for Marburg Virus Disease
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new vaccine for the Marburg virus, a serious disease similar to Ebola. The goal is to assess the vaccine's safety and its ability to trigger an immune response in healthy adults. Participants will receive either the actual cAd3-Marburg vaccine or a placebo (inactive substance) for comparison. The trial seeks healthy adults who have not had the Marburg virus, do not have significant existing health issues, and agree to avoid other vaccines for a specified period. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group of people.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, certain medications like systemic corticosteroids in high doses, anticoagulants, and some investigational drugs are not allowed. It's best to discuss your specific medications with the trial team.
Is there any evidence suggesting that the cAd3-Marburg vaccine is likely to be safe for humans?
Research has shown that the cAd3-Marburg vaccine is safe for people. Studies found that most participants did not experience serious side effects, with 93% handling the vaccine well. Another study reported no safety problems during a 48-week follow-up. Although no vaccine for the Marburg virus has been approved yet, early research on the cAd3-Marburg vaccine's safety appears promising.12345
Why do researchers think this study treatment might be promising?
Researchers are excited about the cAd3-Marburg vaccine because, unlike most treatments that focus on managing symptoms of Marburg Virus Disease, this vaccine aims to prevent infection by triggering an immune response. Traditional care for Marburg Virus Disease primarily involves supportive treatments like rehydration and maintaining electrolyte balance, but this vaccine works differently by using a viral vector to stimulate the body's immune system. Additionally, the cAd3-Marburg vaccine is designed to be administered as a single intramuscular injection, which could simplify deployment and increase accessibility in outbreak situations. This novel approach offers hope for a proactive defense against the virus rather than just a reactive treatment.
What evidence suggests that the cAd3-Marburg vaccine might be an effective treatment for Marburg Virus Disease?
Research has shown that the cAd3-Marburg vaccine, which participants in this trial may receive, yielded promising results in early studies. In tests with animals, including monkeys, this vaccine and similar ones helped prevent Marburg virus disease, indicating effectiveness. Additionally, an earlier study with healthy adults found the vaccine to be safe and capable of triggering an immune response, suggesting potential protection for humans against the Marburg virus.678910
Who Is on the Research Team?
Antonio Gonzalez-Lopez, MD, PhD, MPH
Principal Investigator
Albert B. Sabin Vaccine Institute
Are You a Good Fit for This Trial?
This trial is for healthy adults who can participate in a study to test a new vaccine against Marburg virus. Specific eligibility details are not provided, but typically participants must meet certain health standards and not have conditions that could interfere with the vaccine's evaluation.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single dose of cAd3-Marburg vaccine or placebo intramuscularly on Day 1
Follow-up
Participants are monitored for safety and immunogenicity at multiple timepoints post-vaccination
What Are the Treatments Tested in This Trial?
Interventions
- cAd3-Marburg vaccine
Find a Clinic Near You
Who Is Running the Clinical Trial?
Albert B. Sabin Vaccine Institute
Lead Sponsor
Biomedical Advanced Research and Development Authority
Collaborator